Stem Cell Therapy for Osteoarthritis: 24-Month Patient Outcome Data

Osteoarthritis affects over 500 million people worldwide and is a leading cause of disability among adults over 60. Despite this prevalence, conventional treatment options remain limited: NSAIDs, corticosteroid injections, physical therapy, and eventually joint replacement surgery. Mesenchymal stem cell therapy is being studied as a biologically active option that may support the joint environment in selected candidates.

Why Conventional Treatments Fall Short

Current OA management focuses almost entirely on symptom control rather than disease modification. NSAIDs reduce pain and inflammation but do not slow cartilage loss and carry significant gastrointestinal and cardiovascular risks with long-term use. Corticosteroid injections provide temporary relief but, over multiple cycles, can actually accelerate cartilage degradation. Joint replacement surgery is highly effective but irreversible, carries surgical risks, and requires months of rehabilitation.

What many OA patients need is a careful review of options that may support inflammatory balance, joint function, and recovery planning while setting realistic expectations about what regenerative medicine can and cannot do.

How MSC Injections Work in the Osteoarthritic Joint

The pathophysiology of osteoarthritis involves a self-reinforcing cycle: mechanical damage triggers inflammatory signaling (IL-1β, TNF-α), which activates catabolic enzymes (MMPs, aggrecanases) that degrade cartilage matrix, which causes more mechanical instability, which amplifies the inflammatory signal. MSCs interrupt this cycle through multiple mechanisms:

• Inflammatory balance: MSC signaling is being studied for its role in modulating cytokine pathways involved in cartilage catabolism
• Chondroprotection: MSC-secreted factors are being studied for their potential role in supporting chondrocyte survival and cartilage-matrix balance
• Angiogenesis and repair signaling: Growth-factor signaling may support subchondral bone vascularity and tissue-repair pathways
• Synovial modulation: MSCs are being studied for potential effects on synovitis and joint-environment signaling

Outcome Reviews: What to Ask About

Published and retrospective outcome reviews can be useful, but they should be interpreted carefully. Patient selection, OA grade, imaging findings, cell source, dose, injection technique, rehabilitation, and follow-up all influence reported outcomes. Discuss these factors with a physician before considering any orthobiologic protocol.

• Pain and function scales: Ask how pain and mobility are measured and how meaningful change is defined
• Imaging: Ask whether ultrasound, MRI, or X-ray findings support your candidacy
• OA grade: Early- and mid-stage joint disease may be evaluated differently from advanced joint destruction
• Technique: Ask whether image guidance is used and how sterility is maintained
• Follow-up: Ask what monitoring, rehabilitation, and escalation plan are recommended

What Intra-Articular MSC Injection Looks Like

The procedure is performed as an outpatient treatment under ultrasound or fluoroscopic guidance to ensure precise delivery to the target joint space. A typical single-joint protocol at Renuvia:

• Preparation: Joint is cleaned and local anesthetic is applied (15 minutes)
• Injection: Ultrasound-guided delivery of MSC preparation to the synovial space (5–10 minutes)
• Rest: Patient rests for 30 minutes; mild activity restriction for 48 hours post-injection
• Follow-up: Reassessment at 4 weeks and 3 months; repeat injection considered at 6 months if beneficial and indicated

Who Benefits Most?

The strongest responders in the outcome data were patients who:

• Had grade I–III OA (Kellgren-Lawrence classification) — some residual cartilage present
• Were below age 70 with no significant comorbidities compromising healing capacity
• Received injection alongside physical therapy and joint optimization (weight management, activity modification)
• Had intra-articular injection combined with IV MSC infusion for systemic anti-inflammatory support

Combining MSC Therapy with Other Modalities

Combination protocols may be considered for selected orthopedic candidates after physician evaluation. Depending on the case, a physician may discuss systemic support, targeted joint injection, PRP, rehabilitation, or adjunctive therapies intended to support recovery signaling. These decisions require individualized review and informed consent.